Response to Comments: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease

This document is a response-to-comments notice for MolDX LCD L38341 and records a title revision to 'Prostate Cancer Genomic Classifier Assay for Men with Localized Disease.' It reports the public comment period (10/22/2019–12/06/2019), notice period start (10/22/2020), and effective date (12/06/2020). The provided excerpt contains no specific coverage indications, limitations, or frequency limits — review LCD L38341 for the operative coverage criteria.

"Public comment period for LCD L38341 ran 10/22/2019 through 12/06/2019; notice period begins 10/22/2020 and the LCD becomes effective 12/06/2020."

Sign up to see full coverage criteria, indications, and limitations.